Using two successive pairs of specialized CT scans, a team of Johns Hopkins and Dutch radiologists has produced real-time images of liver tumors dying from direct injection of anticancer drugs into the tumors and their surrounding blood vessels. Within a minute, the images showed whether the targeted chemotherapy did or did not choke off the tumors blood supply and saved patients a month of worry about whether the treatment, known as chemoembolization, was working or not, and whether repeat or more powerful treatments were needed.
Un análisis revela que los médicos que confían en los estudios publicados en las principales revistas científicas para decidir cómo tratar a una mujer con cáncer mamario no estarían recibiendo la información más precisa.
Los médicos estadounidenses dedican casi el 11 por ciento del tiempo de su carrera profesional a la espera de que se resuelvan las reclamaciones por mala práctica médica, según indica una investigación reciente.
El uso de la aspirina parece asociarse con una reducción en el riesgo de cáncer de hígado y de muerte por enfermedad hepática crónica, según un estudio reciente de gran tamaño.
In an effort to better serve their members, two associations are jumping into the magazine publishing business—the Society of Interventional Radiology (SIR) and the National Association of Home Builders (NAHB) have each launched new magazines to better communicate critical information and industry updates to their core groups.
EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, announced today the submission of its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) on January 31, 2013 for the Company s Ablatherm-HIFU (High Intensity Focused Ultrasound) for treatment of low risk, localized prostate cancer. EDAP s PMA submission includes data from the ENLIGHT study, a multi-center U.S. Phase II/III clinical trial that completed the two year follow-up needed to evaluate its primary endpoint in August 2012, as well as data from the Company s extensive worldwide database of treatment information and follow-up data from patients who have undergone HIFU therapy for prostate cancer
ClearRead +Confirm, new software from Riverain Technologies that improves the clarity of conventional chest X-ray images and allows radiologists to rapidly confirm the proper placement of tubes, lines and wires, has received 510(k) clearance from the Food and Drug Administration (FDA)
NCCN announces the availability of NCCN Guidelines for Patients®: Caring for Adolescents and Young Adults, a patient-friendly translation of the NCCN Guidelines® focused on people diagnosed with cancer between the ages of 15 and 39.
Indian stent makers are becoming increasingly viable competitors in international markets, adding another layer to an industry already crowded with a number of players.
IRVINE, Calif.--(BUSINESS WIRE)--Blockade Medical LLC, a privately held company focused on the development of catheter based therapeutic devices for the treatment of cerebral aneurysms, announced today that more than 100 patients have been successfully treated with the Barricade Coil SystemTM. The patients treated, presented with a wide range of cerebral aneurysms and peripheral lesions. All treated patients had positive clinical outcomes without any reported complications.
DAYTON, Ohio--(Healthcare Sales & Marketing Network)--ClearRead +Confirm, new software from Riverain Technologies that improves the clarity of conventional chest X-ray images and allows radiologists to rapidly confirm the proper placement of tubes, lines and wires, has received 510(k) clearance from the Food and Drug Administration (FDA).
Los chequeos de rutina no ayudan a reducir el riesgo de un paciente de morir de enfermedad cardiaca ni de cáncer, sugiere una investigación danesa reciente.
Results from the Symplicity HTN-2, the first randomised clinical trial investigating renal denervation, were published online before print in Circulation, the Journal of the American Heart Association. These data showed patients, who initially received treatment with the Symplicity renal denervation system (n=47), sustained a significant drop in blood pressure (-28/-10 mm Hg [p<0.001]) compared to baseline at 12 months. The 12 month results demonstrated preservation of the benefit at six month follow-up (-32/-12 mm Hg). No device related serious adverse events, no late vascular complications, and no significant decline in kidney function were reported at 12 months.
The initial version of the single, high-power, high-frequency 2.45GHz saline-cooled needle was cleared for use in the USA as part of the Acculis MTA system in 2010. Following two years of global distribution, and in response to customer feedback and growing product demand, Microsulis has updated the device’s design and manufacturing process. Improvements include a refined optically clear moulded handle and improved connection cartridge.
Boston Scientific has announced that the first patient has been enrolled in a study comparing its WallFlex Biliary RX Fully Covered self-expanding metal stent (SEMS) to plastic stents for the treatment of benign bile duct strictures caused by chronic pancreatitis.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos